Ignite Creation Date:
2024-05-05 @ 9:43 PM
Last Modification Date:
2024-10-26 @ 10:08 AM
Study NCT ID:
NCT00943761
Status:
COMPLETED
Last Update Posted:
2021-02-08
First Post:
2009-07-21
Brief Title:
A Study of Vaniprevir MK-7009 in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies MK-7009-028
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase II Open Label Study of MK-7009 Administered Concomitantly With Pegylated Interferon Alfa-2a and Ribavirin to Patients With Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will provide vaniprevir 600 mg or 300 mg twice daily in combination with pegylated interferon peg-IFN and ribavirin RBV to participants with chronic hepatitis C virus HCV infection who did not achieve viral eradication while participating in a prior vaniprevir clinical trial MK-7009-004 NCT00518622 MK-7009-007 NCT00704405 MK-7009-009 NCT00704184 and MK-7009-029 NCT00954993
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2009-013053-15 | EUDRACT_NUMBER | Merck | None |
| 2009_615 | OTHER | None | None |